FE 35A

Drug Profile

FE 35A

Alternative Names: FE35A

Latest Information Update: 23 Aug 2007

Price : $50

At a glance

  • Originator Nippon Kayaku
  • Class Aminoglycosides; Cytostatic antibiotics
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 23 Aug 2007 Discontinued - Preclinical for Cancer in Japan (unspecified route)
  • 28 May 2001 No-Development-Reported for Cancer in Japan (unspecified route)
  • 21 Jan 1999 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top